Literature DB >> 22512984

Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Juan E Grunwald1, Ebenezer Daniel, Gui-Shuang Ying, Maxwell Pistilli, Maureen G Maguire, Judith Alexander, Revell Whittock-Martin, Candace R Parker, Krista Sepielli, Barbara A Blodi, Daniel F Martin.   

Abstract

OBJECTIVE: To describe the methods used for assessment of baseline fundus characteristics from color photography and fluorescein angiography (FA) in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and to describe the relationship between these characteristics and visual acuity.
DESIGN: Randomized, masked, multicenter trial. PARTICIPANTS: This investigation included 1185 participants of the CATT study.
METHODS: Baseline stereoscopic color fundus photographs and FAs of participants in the CATT study were assessed at a central fundus photograph reading center by masked readers. Replicate assessments of random samples of photographs were performed to assess intragrader and intergrader agreements. The association of the lesion characteristics with baseline visual acuity was assessed using analyses of variance and correlation coefficients. MAIN OUTCOME MEASURES: Intragrader and intergrader reproducibility, visual acuity, and lesion characteristics.
RESULTS: Intragrader and intergrader reproducibility showed agreements ranging from 75% to 100% and weighted κ values ranging from 0.48 to 1.0 for qualitative determinations. The intraclass correlation coefficients were 0.96 to 0.97 for quantitative measurements of choroidal neovascularization (CNV) area and total area of CNV lesion. The mean visual acuity varied by the type of pathologic features in the foveal center: 64.5 letters (standard error, 0.7 letters) for fluid only, 59.0 letters (standard error, 0.5 letters) for CNV, and 58.7 letters (standard error, 1.3 letters) for hemorrhage (P<0.001). Fibrotic or atrophic scar present in the lesion, but not under the center of the fovea, also was associated with a markedly reduced visual acuity of 48.4 letters (standard error, 2.2 letters; P<0.0001). Although total area of CNV lesion was correlated weakly with visual acuity when all participants were assessed (Spearman correlation coefficient, ρ = -0.16; P<0.001), the correlation was stronger within patients with predominantly classic lesions (ρ = -0.42; P<0.001).
CONCLUSIONS: These results show that the methodology used for grading CATT fundus images has good reproducibility. As expected, larger total CNV lesion area and pathologic findings such as hemorrhage, fibrosis, and atrophy at baseline are associated with decreased visual acuity.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22512984      PMCID: PMC3401277          DOI: 10.1016/j.ophtha.2012.02.013

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

1.  Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.

Authors:  Srinivas R Sadda; Glenn Stoller; David S Boyer; Barbara A Blodi; Howard Shapiro; Tsontcho Ianchulev
Journal:  Retina       Date:  2010-10       Impact factor: 4.256

2.  Clinicopathologic correlation of choroidal and retinal neovascular lesions in age-related macular degeneration.

Authors:  Michael L Klein; David J Wilson
Journal:  Am J Ophthalmol       Date:  2011-01       Impact factor: 5.258

3.  Retinal angiomatous proliferation in age-related macular degeneration.

Authors:  L A Yannuzzi; S Negrão; T Iida; C Carvalho; H Rodriguez-Coleman; J Slakter; K B Freund; J Sorenson; D Orlock; N Borodoker
Journal:  Retina       Date:  2001       Impact factor: 4.256

4.  Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation.

Authors:  B A Lafaut; K U Bartz-Schmidt; C Vanden Broecke; S Aisenbrey; J J De Laey; K Heimann
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

5.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  Deep retinal vascular anomalous complexes in advanced age-related macular degeneration.

Authors:  M E Hartnett; J J Weiter; G Staurenghi; A E Elsner
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

7.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

8.  The nature of focal areas of hyperfluorescence or hot spots imaged with indocyanine green angiography.

Authors:  Luiz Henrique Schurig Fernandes; K Bailey Freund; Lawrence A Yannuzzi; Richard F Spaide; Sheau J Huang; Jason S Slakter; John A Sorenson
Journal:  Retina       Date:  2002-10       Impact factor: 4.256

9.  A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol.

Authors:  Roy W Beck; Pamela S Moke; Andrew H Turpin; Frederick L Ferris; John Paul SanGiovanni; Chris A Johnson; Eileen E Birch; Danielle L Chandler; Terry A Cox; R Clifford Blair; Raymond T Kraker
Journal:  Am J Ophthalmol       Date:  2003-02       Impact factor: 5.258

10.  Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Authors:  Peter K Kaiser; Barbara A Blodi; Howard Shapiro; Nisha R Acharya
Journal:  Ophthalmology       Date:  2007-07-12       Impact factor: 12.079

View more
  41 in total

1.  Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Authors:  Ebenezer Daniel; James Shaffer; Gui-shuang Ying; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Maureen G Maguire
Journal:  Ophthalmology       Date:  2015-12-08       Impact factor: 12.079

2.  VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).

Authors:  Stephanie A Hagstrom; Gui-shuang Ying; Gayle J T Pauer; Gwen M Sturgill-Short; Jiayan Huang; Maureen G Maguire; Daniel F Martin
Journal:  JAMA Ophthalmol       Date:  2014-05       Impact factor: 7.389

3.  Bevacizumab modulates retinal pigment epithelial-to-mesenchymal transition via regulating Notch signaling.

Authors:  Jing-Jing Zhang; San-Jun Chu; Xiao-Lei Sun; Ting Zhang; Wei-Yun Shi
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

4.  A new scale for the assessment of conjunctival bulbar redness.

Authors:  Ilaria Macchi; Vatinee Y Bunya; Mina Massaro-Giordano; Richard A Stone; Maureen G Maguire; Yuanjie Zheng; Min Chen; James Gee; Eli Smith; Ebenezer Daniel
Journal:  Ocul Surf       Date:  2018-06-06       Impact factor: 5.033

5.  Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Juan E Grunwald; Maxwell Pistilli; Ebenezer Daniel; Gui-Shuang Ying; Wei Pan; Glenn J Jaffe; Cynthia A Toth; Stephanie A Hagstrom; Maureen G Maguire; Daniel F Martin
Journal:  Ophthalmology       Date:  2016-10-27       Impact factor: 12.079

6.  Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization.

Authors:  Ikuko Kachi; Tsutomu Yasukawa; Aki Kato; Noriaki Takase; Hiroshi Morita; Ayae Kubota; Yoshio Hirano; Akiyoshi Uemura; Yuichiro Ogura
Journal:  Jpn J Ophthalmol       Date:  2016-02-26       Impact factor: 2.447

7.  Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Ebenezer Daniel; Juan E Grunwald; Benjamin J Kim; Maureen G Maguire; Glenn J Jaffe; Cynthia A Toth; Frederick L Ferris; Daniel F Martin; James Shaffer; Gui-Shuang Ying
Journal:  Ophthalmol Retina       Date:  2017 Jan-Feb

8.  Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT).

Authors:  Gui-shuang Ying; Maureen G Maguire; Ebenezer Daniel; Frederick L Ferris; Glenn J Jaffe; Juan E Grunwald; Cynthia A Toth; Jiayan Huang; Daniel F Martin
Journal:  Ophthalmology       Date:  2015-09-15       Impact factor: 12.079

9.  Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.

Authors:  Maureen G Maguire; Ebenezer Daniel; Ankoor R Shah; Juan E Grunwald; Stephanie A Hagstrom; Robert L Avery; Jiayan Huang; Revell W Martin; Daniel B Roth; Alessandro A Castellarin; Sophie J Bakri; Stuart L Fine; Daniel F Martin
Journal:  Ophthalmology       Date:  2013-05-22       Impact factor: 12.079

10.  Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

Authors:  Stephanie A Hagstrom; Gui-Shuang Ying; Gayle J T Pauer; Gwen M Sturgill-Short; Jiayan Huang; David G Callanan; Ivana K Kim; Michael L Klein; Maureen G Maguire; Daniel F Martin
Journal:  Ophthalmology       Date:  2013-01-18       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.